Clinical features and treatment of patients according to relapse status after acute presentation
| Clinical feature . | No relapse (n = 312, 70.4%) . | Relapse (n = 131, 29.6%) . | P . |
|---|---|---|---|
| Duration of follow-up (IQR), y | 8.4 (5.7-10.4) | 8.7 (5.6-10.9) | .39 |
| Age at presentation, y | 45.0 | 45.1 | .49 |
| Age <25 y at presentation, n (%) | 27 (8.7) | 11 (8.4) | .93 |
| Gender (male/female), n (%) | 79 (25.3)/233 (74.7) | 43 (32.8)/88 (67.2) | .11 |
| Blood counts at presentation | |||
| Hemoglobin, g/L | 82 | 95 | <.001 |
| Platelets, ×109/L | 20 | 34 | <.001 |
| Absolute reticulocytes, ×109/L | 158 | 159 | .95 |
| Ethnicity, n (%) | .019 | ||
| Caucasian | 197 (63.1) | 69 (52.7) | |
| Black African | 32 (10.2) | 13 (9.9) | |
| Black Caribbean | 22 (7.1) | 22 (16.8) | |
| Asian | 26 (8.3) | 14 (10.7) | |
| Mixed | 5 (1.6) | 4 (3.1) | |
| Other | 6 (1.9) | 3 (2.3) | |
| Unknown | 24 (7.7) | 6 (4.6) | |
| Associated conditions, n (%) | <.001 | ||
| Idiopathic | 202 (64.7) | 87 (66.4) | |
| HIV | 17 (5.4) | 3 (2.3) | |
| Drug-induced | 5 (1.6) | 0 (0) | |
| Other autoimmune disease | 51 (16.3) | 27 (20.6) | |
| Pancreatitis | 11 (3.5) | 0 (0) | |
| Pregnancy | 10 (3.2) | 8 (6.1) | |
| Other | 16 (5.1) | 7 (5.3) | |
| Treatment at acute presentation, n (%) | |||
| Corticosteroid | 267 (85.6) | 116 (88.5) | .97 |
| Rituximab | 169 (54.2) | ||
| Mycophenolate mofetil | 2 (0.6) | 0 | |
| Caplacizumab | 7 (2.2) | 3 (2.3) |
| Clinical feature . | No relapse (n = 312, 70.4%) . | Relapse (n = 131, 29.6%) . | P . |
|---|---|---|---|
| Duration of follow-up (IQR), y | 8.4 (5.7-10.4) | 8.7 (5.6-10.9) | .39 |
| Age at presentation, y | 45.0 | 45.1 | .49 |
| Age <25 y at presentation, n (%) | 27 (8.7) | 11 (8.4) | .93 |
| Gender (male/female), n (%) | 79 (25.3)/233 (74.7) | 43 (32.8)/88 (67.2) | .11 |
| Blood counts at presentation | |||
| Hemoglobin, g/L | 82 | 95 | <.001 |
| Platelets, ×109/L | 20 | 34 | <.001 |
| Absolute reticulocytes, ×109/L | 158 | 159 | .95 |
| Ethnicity, n (%) | .019 | ||
| Caucasian | 197 (63.1) | 69 (52.7) | |
| Black African | 32 (10.2) | 13 (9.9) | |
| Black Caribbean | 22 (7.1) | 22 (16.8) | |
| Asian | 26 (8.3) | 14 (10.7) | |
| Mixed | 5 (1.6) | 4 (3.1) | |
| Other | 6 (1.9) | 3 (2.3) | |
| Unknown | 24 (7.7) | 6 (4.6) | |
| Associated conditions, n (%) | <.001 | ||
| Idiopathic | 202 (64.7) | 87 (66.4) | |
| HIV | 17 (5.4) | 3 (2.3) | |
| Drug-induced | 5 (1.6) | 0 (0) | |
| Other autoimmune disease | 51 (16.3) | 27 (20.6) | |
| Pancreatitis | 11 (3.5) | 0 (0) | |
| Pregnancy | 10 (3.2) | 8 (6.1) | |
| Other | 16 (5.1) | 7 (5.3) | |
| Treatment at acute presentation, n (%) | |||
| Corticosteroid | 267 (85.6) | 116 (88.5) | .97 |
| Rituximab | 169 (54.2) | ||
| Mycophenolate mofetil | 2 (0.6) | 0 | |
| Caplacizumab | 7 (2.2) | 3 (2.3) |